St. Baishi Squibb's clinical phase 2 trial on the treatment of plaque-like psoriasis patients in the new drug BMS-986165 reaches the main endpoint

September 13, the company'scompany, BMS,(announced that it isthe treatment of psoriasis) in the research of new drug(in the treatment of patients with moderate to severe plaque psoriasis patients clinical 2trial(the main end of the efficacy)After 12 weeks of taking BMS-986165, the psoriasis area and critical ity index (PASI) scores in most patients decreased by more than 75% (PASI 75), and in some patients the PASI score decreased by more than 90% (PASI 90) or even achieved complete removal of lesions (PASI 100)BMS-986165BMS is an innovative oral-specific TYK2 inhibitor developed by BMSTYK2 is an intracellular signaling protein kinase that mediates immune and inflammatory signaling pathways caused by cytokinesThe TYK2 signaling pathway is thought to be associated with the pathology of a variety of immunomediated diseases, including psoriasis, lupus erythematosus, and inflammatory bowel diseasein a multicenter called IM011-011, in a randomized double-blind clinical phase 2 trial with placebo control, 267 patients with moderate to severe psoriasis were randomly divided into groups and treated with different doses of BMS-986165 and placeboresults showed that 67%-75% of patients in the patient group who received a dose of 3 mg per dose, 2 times or more of BMS-986165 per dose, met the PASI 75 standard (P 0.001)Of these, 43%-44% of patients reached PASI 90 and 9%-25% reached PASI 100, BMS has initiated a clinical Phase 3 trial to test BMS-986165 for patients with moderate to severe psoriasis, a study that is being registered with patientsat the same time, a clinical phase 2 trial to test the efficacy of BMS-986165 for the treatment of lupus and Crohn's disease is also under way